{
    "clinical_study": {
        "@rank": "60530", 
        "arm_group": [
            {
                "arm_group_label": "Titration Schedule 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Titration Schedule 2", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 3 study designed to evaluate the safety and tolerability of two titration\n      schedules for ALKS 5461."
        }, 
        "brief_title": "A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index of 18-40 kg/m2\n\n          -  Have a diagnosis of MDD\n\n          -  Have a currant major depressive episode (MDE) lasting 8 weeks to 24 months\n\n          -  Have been treated with an adequate dose of an approved antidepressant during the\n             current MDE for at least 8 weeks\n\n          -  Have an inadequate response to currant antidepressant treatment\n\n          -  Agree to use an approved method of birth control for the duration of the study\n\n          -  Additional criteria may apply\n\n        Exclusion Criteria:\n\n          -  Currently pregnant or breastfeeding\n\n          -  History of or current infection with Hepatitis B Virus, Hepatitis C Virus or Human\n             Immunodeficiency Virus (HIV)\n\n          -  Have experienced hallucinations, delusions, or any psychotic symptoms in the current\n             MDE\n\n          -  Have used opioid agonists (eg, codeine, oxycodone, tramadol, or morphine) or opioid\n             antagonists (eg, naloxone, naltrexone) within 14 days\n\n          -  Have received electroconvulsive therapy treatment within the last 5 years\n\n          -  Have attempted suicide within the past 2 years\n\n          -  Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or\n             opioid antagonists (eg, naltrexone, naloxone)\n\n          -  Have had a significant blood loss or blood donation with 60 days of screening\n\n          -  Additional criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085135", 
            "org_study_id": "ALK5461-210"
        }, 
        "intervention": {
            "arm_group_label": [
                "Titration Schedule 1", 
                "Titration Schedule 2"
            ], 
            "description": "Sublingual tablet taken once daily", 
            "intervention_name": "ALKS 5461", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "depression", 
            "major depressive disorder", 
            "Alkermes", 
            "ALKS 5461", 
            "samidorphan", 
            "buprenorphine"
        ], 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32256"
                    }, 
                    "name": "Alkermes Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Alkermes Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Alkermes Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Charles", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63304"
                    }, 
                    "name": "Alkermes Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Staten Island", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10305"
                    }, 
                    "name": "Alkermes Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45417"
                    }, 
                    "name": "Alkermes Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Allentown", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18104"
                    }, 
                    "name": "Alkermes Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellevue", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98007"
                    }, 
                    "name": "Alkermes Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy", 
        "overall_contact": {
            "email": "Jean-Francois.Gagne@INCResearch.com", 
            "last_name": "Jean-Francois Gagne", 
            "phone": "919-257-6569"
        }, 
        "overall_official": {
            "affiliation": "Alkermes", 
            "last_name": "Randall Marshall, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability:  Number and percent of subjects experiencing a treatment emergent adverse event (TEAE)", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085135"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alkermes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alkermes", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}